Somewhat Positive Media Coverage Extremely Likely to Affect Exelixis (EXEL) Share Price

Press coverage about Exelixis (NASDAQ:EXEL) has trended somewhat positive this week, according to AlphaOne. The research firm, a subsidiary of Accern, ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Exelixis earned a daily sentiment score of 0.01 on AlphaOne’s scale. AlphaOne also assigned news headlines about the biotechnology company an impact score of 91 out of 100, meaning that recent media coverage is extremely likely to have an effect on the stock’s share price in the near term.

These are some of the news headlines that may have impacted AlphaOne Sentiment’s scoring:

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Shares of Exelixis (NASDAQ:EXEL) traded up 0.10% during mid-day trading on Friday, hitting $19.26. The stock had a trading volume of 3,678,824 shares. The company’s 50 day moving average price is $20.44 and its 200 day moving average price is $19.81. Exelixis has a 12-month low of $7.20 and a 12-month high of $24.85. The stock has a market cap of $5.63 billion, a P/E ratio of 917.14 and a beta of 1.98.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Monday, May 1st. The biotechnology company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06. Exelixis had a net margin of 1.37% and a return on equity of 126.82%. The firm had revenue of $80.90 million during the quarter, compared to analysts’ expectations of $65.23 million. During the same period in the prior year, the company earned ($0.27) EPS. The firm’s revenue was up 425.3% on a year-over-year basis. Equities research analysts predict that Exelixis will post $0.18 EPS for the current fiscal year.

Several analysts have weighed in on EXEL shares. Zacks Investment Research downgraded Exelixis from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 3rd. Stifel Nicolaus cut Exelixis from a “buy” rating to a “hold” rating and set a $22.00 price objective for the company. in a report on Tuesday, February 28th. They noted that the move was a valuation call. CIBC began coverage on Exelixis in a report on Thursday, March 16th. They issued a “market perform” rating for the company. Oppenheimer Holdings, Inc. began coverage on Exelixis in a report on Thursday, March 16th. They issued a “market perform” rating for the company. Finally, Cann started coverage on Exelixis in a report on Wednesday, March 15th. They issued a “positive” rating for the company. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Exelixis currently has a consensus rating of “Buy” and a consensus target price of $18.37.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive Media Coverage Extremely Likely to Affect Exelixis (EXEL) Share Price” was originally published by Markets Daily and is owned by of Markets Daily. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.themarketsdaily.com/2017/06/16/somewhat-favorable-news-coverage-extremely-likely-to-impact-exelixis-exel-stock-price-updated-updated.html.

In related news, Director Stelios Papadopoulos sold 10,000 shares of the business’s stock in a transaction dated Monday, March 20th. The shares were sold at an average price of $21.66, for a total transaction of $216,600.00. Following the completion of the sale, the director now owns 1,238,471 shares of the company’s stock, valued at approximately $26,825,281.86. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Patrick J. Haley sold 5,000 shares of the business’s stock in a transaction dated Tuesday, May 30th. The shares were sold at an average price of $18.46, for a total transaction of $92,300.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 765,468 shares of company stock worth $16,847,040. Company insiders own 5.10% of the company’s stock.

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply